We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aclaris Therapeutics Inc | NASDAQ:ACRS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.84% | 1.20 | 1.17 | 1.26 | 1.20 | 1.16 | 1.20 | 445,216 | 21:00:05 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Flynn James E |
2. Issuer Name
and
Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
780 THIRD AVENUE, 37TH FLOOR, |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10017 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 5/9/2019 | S | 261345 | D | $6.1575 (1) | 4220443 | I | Through Deerfield Partners, L.P. (2) (3) | ||
Common Stock | 5/9/2019 | S | 172800 | D | $6.1575 (1) | 1238828 | I | Through Deerfield Special Situations Fund, L.P. (2) (3) | ||
Common Stock | 5/10/2019 | S | 108696 | D | $6.0492 (4) | 4111747 | I | Through Deerfield Partners, L.P. (2) (3) | ||
Common Stock | 5/10/2019 | S | 71869 | D | $6.0492 (4) | 1166959 | I | Through Deerfield Special Situations Fund, L.P. (2) (3) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Remarks:
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn. See footnote (1) |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Flynn James E
780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017 |
|
X |
|
|
|
Deerfield Mgmt L.P.
780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017 |
|
X |
|
|
|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
780 THIRD AVENUE, 37TH FLOOR NEW YORK, NY 10017 |
|
X |
|
|
|
Deerfield Special Situations Fund, L.P.
780 3RD AVENUE 37TH FLOOR NEW YORK, NY 10017 |
|
|
|
Possible Member of a 10% Group | |
DEERFIELD PARTNERS, L.P.
780 THIRD AVENUE 37TH FLOOR NEW YORK, NY 10017 |
|
X |
|
|
Signatures
|
||
/s/ Jonathan Isler, Attorney-in-Fact | 5/13/2019 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Aclaris Therapeutics Chart |
1 Month Aclaris Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions